Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 6/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 6/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 6/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13416954 | 0.95 | ITGB3 (0.43) | ITGB3ITGA2BPRSS1PRSS2PRSS3 | |
| SCHEMBL13416664 | 0.88 | TGM2 (0.45) | FOLH1 | |
| SCHEMBL13416923 | 0.88 | PRSS1 (0.44) | ITGB3ITGA2BPRSS1PRSS2PRSS3 | |
| SCHEMBL13417040 | 0.85 | NAALAD2 (0.43) | PRSS1FOLH1 | |
| SCHEMBL13416587 | 0.84 | ITGB1 (0.39) | ITGB3ITGA2BPRSS1 | |
| SCHEMBL13416773 | 0.83 | TGM2 (0.46) | FOLH1 | |
| SCHEMBL13396736 | 0.83 | ITGB3 (0.42) | ITGB3ITGA2BPRSS1PRSS2PRSS3 | |
| SCHEMBL13416590 | 0.83 | TMPRSS15 (0.41) | PRSS1 | |
| SCHEMBL13416691 | 0.83 | ALDH1A1 (0.46) | — | |
| SCHEMBL13416915 | 0.83 | PRSS1 (0.45) | ITGB3ITGA2BPRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
| WO-2008095841-A2 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | ITGB3 211/4885ITGA2B 313/4885PRSS1 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.